Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 8/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15453824 | 1.00 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL7183631 | 1.00 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL7189862 | 1.00 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28988286 | 0.99 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28334883 | 0.99 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29041685 | 0.99 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28447938 | 0.99 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28404493 | 0.99 | SLC28A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28732799 | 0.89 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL29178060 | 0.89 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005090370-A1 | PHARMACOLOGICALLY ACTIVE AGENTS CONTAINING ESTERIFIED PHOSPHONATES AND METHODS FOR USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | claimed |
| EP-2518085-A1 | IL-17 receptor A antigen binding proteins | Kirin-Amgen, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2493479-A1 | METHODS OF TREATING VIRAL ASSOCIATED DISEASES | Chimerix, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2462152-A1 | COMPOSITION AND METHODS OF TREATING VIRAL INFECTIONS AND VIRAL INDUCED TUMORS | Chimerix, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011053812-A1 | METHODS OF TREATING VIRAL ASSOCIATED DISEASES | CHIMERIX, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011017253-A1 | COMPOSITION AND METHODS OF TREATING VIRAL INFECTIONS AND VIRAL INDUCED TUMORS | CHIMERIX, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011011710-A1 | METHODS OF TREATING VIRAL INFECTIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |